Reference
Meng P, et al. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation. Lung Cancer 146: 358-361, Aug 2020. Available from: URL: http://doi.org/10.1016/j.lungcan.2020.05.036
Rights and permissions
About this article
Cite this article
Antineoplastics. Reactions Weekly 1821, 39 (2020). https://doi.org/10.1007/s40278-020-83159-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-83159-5